Sparkle of Hope Gala Chair
Sparkle of Hope Gala Chair
CHRISTOPHER HITE Vice Chairman Royalty Pharma
ANNA KAZANCHYAN Founder and CEO Saghmos Therapeutics
Chris has over 25 years of experience advising biopharmaceutical companies on mergers and acquisitions and capital formation. Prior to joining Royalty Pharma in 2020, Chris was an investment banker at Citi where he was the Global Head of Healthcare for nearly 12 years and most recently a vice chairman of Banking,
Anna Kazanchyan, M.D., is CEO and Founder of Saghmos Therapeutics and has over 25 years of experience at marquee Wall Street firms, biopharmaceutical companies and as an entrepreneur. She has a unique combination of equity research, business and clinical strategy as well as business development experience and expertise. Dr.
Capital Markets and Advisory (“BCMA”) and also sat on the Executive Committee of BCMA. Prior to joining Citi, Chris was the Global Head of Healthcare Investment Banking at Lehman Brothers. Chris serves on the Board of Trustees at Lehigh University, the Board of Advisors of Faster Cures, a center of the Milken Institute, the Board of Directors of Kailera Therapeutics and served on the Board of Directors of Acceleron Pharma Inc. (Nasdaq: XLRN) until its acquisition by Merck in November 2021 for $11.5 billion. Chris has a BS from Lehigh University and a JD and MBA from the University of Pittsburgh.
Kazanchyan has served as a member of the Board of Directors for several publicly traded biopharmaceutical companies and as a Coach for the WomenInBio’s BoardRoom Ready initiative. She was previously Managing Partner of Primary i-Research, where she provided due diligence to leading multi-billion dollar healthcare investment funds and evaluated investment prospects of hundreds of biopharma companies based on the scientific, clinical, regulatory, and commercial outlook for their products. In addition, Dr. Kazanchyan was retained as an Executive Advisor by CEOs and Boards of global biopharmaceutical companies on matters of high strategic importance related to business development, competitive intelligence, regulatory strategy, marketing and commercial/competitive landscape. Previously, she was SVP, Business Development and Product Development at Ovid Therapeutics. Dr. Kazanchyan was also Senior Biotechnology Analyst at Wells Fargo Securities and was a member of the #1 and #2 Institutional-Investor ranked Biotechnology Equity Research teams at Goldman Sachs and Citigroup, respectively. She received an M.D. from Harvard Medical School and a B.A. in Biology, summa cum laude, from Clark University.
Made with FlippingBook - Online Brochure Maker